194 related articles for article (PubMed ID: 24293258)
21. Insights into JAK2-V617F mutation in CML.
Bocchia M; Vannucchi AM; Gozzetti A; Guglielmelli P; Poli G; Crupi R; Defina M; Bosi A; Francesco L
Lancet Oncol; 2007 Oct; 8(10):864-6. PubMed ID: 17913657
[No Abstract] [Full Text] [Related]
22. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
de Conchon MRM; Costa JL; Novaes MMY; Dorlhiac-Llacer PE; de Alencar Fischer Chamone D; Bendit I
Int J Hematol; 2008 Sep; 88(2):243-245. PubMed ID: 18626727
[No Abstract] [Full Text] [Related]
23. JAK2-V617F and BCR-ABL--double jeopardy?
Krämer A
Leuk Res; 2008 Oct; 32(10):1489-90. PubMed ID: 18439674
[No Abstract] [Full Text] [Related]
24. Insights into JAK2-V617F mutation in CML.
Büsche G; Hussein K; Bock O; Kreipe H
Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
[No Abstract] [Full Text] [Related]
25. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
[TBL] [Abstract][Full Text] [Related]
26. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
27. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Pingali SR; Mathiason MA; Lovrich SD; Go RS
Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
[TBL] [Abstract][Full Text] [Related]
28. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
29. The incidence of co-existing BCR-ABL1 and JAK2 V617F rearrangements: implications for molecular diagnostics.
McCarron SL; Haslam K; Crampe M; Langabeer SE
Lab Hematol; 2012 Dec; 18(4):20-1. PubMed ID: 23253862
[No Abstract] [Full Text] [Related]
30. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
31. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
[No Abstract] [Full Text] [Related]
32. Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.
Park SH; Chi HS; Cho YU; Jang S; Park CJ; Kim DY; Lee JH; Lee KH
Ann Lab Med; 2013 May; 33(3):229-32. PubMed ID: 23667855
[No Abstract] [Full Text] [Related]
33. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J
J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476
[TBL] [Abstract][Full Text] [Related]
34. Philadelphia chromosome in chronic myelogenous leukemia: confirmation of cytogenetic diagnosis in Ph positive and negative cases by fluorescence in situ hybridization.
Acar H; Stewart J; Connor MJ
Cancer Genet Cytogenet; 1997 Apr; 94(2):75-8. PubMed ID: 9109930
[TBL] [Abstract][Full Text] [Related]
35. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
36. Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis.
Ninomiya S; Kanemura N; Tsurumi H; Kasahara S; Hara T; Yamada T; Moriwaki H
Int J Hematol; 2011 Jun; 93(6):806-810. PubMed ID: 21523337
[TBL] [Abstract][Full Text] [Related]
37. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.
Hussein K; Bock O; Theophile K; Seegers A; Arps H; Basten O; Grips KH; Franz-Werner J; Büsche G; Kreipe H
Leukemia; 2008 May; 22(5):1059-62. PubMed ID: 17972958
[No Abstract] [Full Text] [Related]
38. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
Krämer A; Reiter A; Kruth J; Erben P; Hochhaus A; Müller M; Cross NC; Jones AV; Ho AD; Hensel M
Lancet Oncol; 2007 Jul; 8(7):658-60. PubMed ID: 17613428
[No Abstract] [Full Text] [Related]
39. A Philadelphia negative chronic myelogenous leukemia with the chimeric BCR/ABL gene on chromosome 9 and a b3-a2 splice junction.
Macera MJ; Smith LJ; Frankel E; Szabo P; Verma RS
Cancer Genet Cytogenet; 1998 Mar; 101(2):143-7. PubMed ID: 9494617
[TBL] [Abstract][Full Text] [Related]
40. Detection of the Philadelphia chromosome in paraffin-embedded tissue by fluorescence in situ hybridization.
Brynes RK; McCourty A; Ho JP; Traweek ST; Snyder DS; Slovak ML
Mod Pathol; 1994 Jun; 7(5):565-9. PubMed ID: 7937723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
